The CRISPR THERAPTC (CRSP) Given Consensus Recommendation of “Strong Buy” by Analysts – DailyQuint
|
The CRISPR THERAPTC (CRSP) Given Consensus Recommendation of “Strong Buy” by Analysts
DailyQuint Shares of CRISPR THERAPTC (NASDAQ:CRSP) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating. Intellia Therapeutics' (NTLA) Buy Rating Reiterated at Jefferies Group LLC |
